United States: Clarifying The Enabling Obligation Of The Patent Act: Amgen Inc. v. Sanofi - Winston & Strawn LLP

Mondaq

23 Jun 2023 0 shares 1 views

United States: Clarifying The Enabling Obligation Of The Patent Act: Amgen Inc. v. Sanofi - Winston & Strawn LLP

Mondaq

Published 23 Jun 2023

In a unanimous decision issued May 18, 2023, the Supreme Court found that certain claims of Amgen Inc.'s patents for PCSK9-inhibiting antibodies are too broad to enable a claim...

Full Article

United States: Understanding SuperValu: Scienter In FCA Claims Hinges On Subjective Beliefs - Winston & Strawn LLP

Mondaq 16 Jun 2023

On June 1, 2023, the Supreme Court of the United States issued its decision in the most-watched False Claims Act ("FCA") case of..

United States: SEC Responds To Coinbase Petition For Regulation Of Digital Assets - Winston & Strawn LLP
Mondaq 02 Jun 2023
United States: Ruling On Enablement Requirement Of The Patent Act Has Wide Implications - Reinhart Boerner Van Deuren s.c.
Mondaq 01 Jun 2023

United States: Clarifying The Enabling Obligation Of The Patent Act: Amgen Inc. v. Sanofi - Winston & Strawn LLP

United States: Clarifying The Enabling Obligation Of The Patent Act: Amgen Inc. v. Sanofi - Winston & Strawn LLP

You might like

Related news coverage

United States: Understanding SuperValu: Scienter In FCA Claims Hinges On Subjective Beliefs - Winston & Strawn LLP

Advertisement